2023 Guidance and Q3 Earnings

Clear momentum driving strong year-to- date performance Delivered 13%¹ sales growth, 14%¹ adj. operating profit growth Profitable, resilient growth across portfolio: Vaccines +21%¹ Specialty Medicines +14% General Medicines +5% New products launched since 20172 delivered £7.8 billion year to date, with c.80% from Vaccines and Specialty Q3 2023 performance Sales £8.1bn, +10% +16%' Adj. EPS 50.4p, +17% +25% Adj. operating profit £2.8bn, +15% +22% Dividend per share 14p Full-year 2023 guidance: upgraded¹ Sales growth: 12-13% Adj. operating profit growth: 13-15% Adj. EPS growth: 17-20% 1 GSK Absolute values at actual exchange rates (AER); changes at CER, unless stated otherwise. 1. Excluding COVID-19 solutions 2. Product approvals since 2017 include: Zejula, Trelegy. Shingrix, Juluca, Dovato, Duvroq, Rukobia, Blenrep, Cabenuva, Jemperli, Apretude, Arexvy 5

View entire presentation